Fact-check: two trialists interpret the tirzepatide data (CMHC)

What the video covers

Dr. Anne Peters of the University of Southern California interviews Dr. Juan Frias, principal investigator of SURPASS-2 and an investigator in the SURMOUNT program, for about 17 minutes. They cover his experience with tirzepatide in trials and clinic, whether it is a glucose drug or a weight drug, how to move someone from a maximal GLP-1 dose, the practical nuisance of prescribing a new pen strength every four weeks, the oral contraceptive caution, and how to think about patients with cardiovascular disease before a tirzepatide outcomes trial has reported.

What it gets right

The trial facts are accurate. SURMOUNT-1 enrolled people without diabetes; the video's "up to 36 percent losing at least 25 percent" and "over 90 percent losing at least 5 percent" match the published 15 mg arm (36.2 percent and 91 percent respectively; PubMed 35658024). The SURPASS-2 detail that A1c fell by about 0.8 points in the first four weeks on 2.5 mg is from that trial's time course (PubMed 34170647). The label statements are right: start at 2.5 mg weekly for four weeks, then increase in 2.5 mg steps at least four weeks apart, to a maximum of 15 mg, which is 20 weeks to the top dose at the fastest permitted pace. The oral contraceptive caution is quoted correctly: the labels advise switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase, because the temporary slowing of gastric emptying lowers the peak concentration of oral contraceptives.

The cardiovascular reasoning was the right reasoning for its time: tirzepatide had cardiovascular safety data from a meta-analysis and SURPASS-4 but no proven benefit, so in a patient with established atherosclerotic disease Dr. Frias preferred an agent with outcome data or added an SGLT2 inhibitor.

What it leaves out or overstates

Two things are now out of date. Zepbound was approved for chronic weight management in November 2023, so the "fast track" and "studies still ongoing" remarks are history. SURPASS-CVOT has since reported, and the cardiovascular discussion should be read as the state of play in 2023, not now.

One piece of advice is explicitly the speaker's practice rather than the label. Dr. Frias says he is comfortable starting at 5 mg in a patient who has tolerated a maximal GLP-1 dose. He also says, in the same breath, that the label says to start at 2.5 mg and that the transition has not been studied in a trial. Both labels still say start at 2.5 mg, and the 2.5 mg dose is described as a starting dose for initiation, not as an effective dose for glycaemic control. A viewer should take the label, not the anecdote, into a conversation with their prescriber.

The video does not cover adverse events beyond "GI side effects if you go too fast", nor does it mention the boxed warning about thyroid C-cell tumours in rodents that both labels carry.

Where to go next

The TCOYD video next in the playlist puts tirzepatide and semaglutide side by side. The Tirzepatide Hub has a dated titration planner built on the four-week rule, and the GLP-1 Starter site covers what to expect in the first weeks. Read the FormBlends tirzepatide guide at formblends.com. Compounded tirzepatide, including the product FormBlends offers, is not FDA approved and is not interchangeable with the pens discussed here.